Vaxcyte Inc. is a clinical-stage vaccine company. It is engaged in developing a spectrum conjugate and protein vaccines to prevent or treat bacterial infectious diseases. Its lead candidate, VAX-24, is a Phase III-ready 24-valent, carrier-sparing pneumococcal conjugate vaccine (PCV) being developed for the prevention of invasive pneumococcal disease (IPD). VAX-31, the Companyâs next generation 31-valent PCV is developed for the prevention of IPD in adults. Its pipeline also includes VAX-A1, VAX-PG, and VAX-GI. VAX-A1, a novel conjugate vaccine candidate designed to prevent disease caused by Group A Streptococcus (Group A Strep). VAX-PG, a novel protein vaccine candidate targeting pathogen responsible for periodontitis, a chronic oral inflammatory disease. VAX-GI, a novel preclinical vaccine candidate being developed as a preventative treatment for dysentery and shigellosis. Its technology platform includes advanced chemistry and the XpressCF cell-free protein synthesis platform.

Employees

254

Sector

Biotechnology & Medical Research

Calendar

03/11/2024 - Q3 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Quotes

Date	Price	Change	Volume
09/09/24	115.28 $	+3.32%	3,328,795
06/09/24	111.58 $	-0.46%	2,346,199
05/09/24	112.10 $	+2.70%	5,156,130
04/09/24	109.15 $	-0.91%	2,388,717

Delayed Quote Nasdaq, September 09, 2024 at 09:00 pm

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

115.28USD

Average target price

145.00USD

Spread / Average Target

+25.78%

Consensus

Profit revisions

Estimate revisions

Quarterly earnings, Rate of surprise

Company calendar

Market Closed - Nasdaq Other stock markets 21:00:00 09/09/2024 BST			5-day change	1st Jan Change
115.28 ^USD	+3.32%		+42.74%	+83.57%

01:15pm	Analyst recommendations: Apple, Oracle, Progressive, Dollar Tree...
11:38am	Mizuho Boosts Price Target on Vaxcyte to $163 From $113, Maintains Outperform Rating	MT

Capitalization	14.26B 1,089B	P/E ratio 2024 *	-26.6x	P/E ratio 2025 *	-23.3x
Enterprise value	14.26B 1,089B	EV / Sales 2024 *	-	EV / Sales 2025 *	-
Free-Float	98.13%	Yield 2024 *	-	Yield 2025 *	-

Analyst recommendations: Apple, Oracle, Progressive, Dollar Tree...	12:15pm
Mizuho Boosts Price Target on Vaxcyte to $163 From $113, Maintains Outperform Rating	10:38am	MT
Health Care Helped By Defensive Bias - Health Care Roundup	09-06	DJ
Vaxcyte Closes $1.5 Billion Offering of Shares, Warrants	09-06	MT
Vaxcyte Prices $1.3 Billion Offering of Shares, Warrants	09-05	MT
Health Care Losses Limited By Vaxcyte's Surge - Health Care Roundup	09-03	DJ
Vaxcyte Starts $1 Billion Underwritten Public Offering	09-03	MT
Sector Update: Health Care Stocks Decline Late Afternoon	09-03	MT
Sector Update: Health Care Stocks Retreat in Afternoon Trading	09-03	MT
Sector Update: Health Care	09-03	MT
Vaxcyte Shares Rise After Plans for Phase 3 Trial of 31-Valent Pneumococcal Conjugate Vaccine Candidate	09-03	MT
Vaxcyte's shares hit record high on early data on pneumococcal vaccine	09-03	RE
Sector Update: Health Care Stocks Lean Lower Pre-Bell Tuesday	09-03	MT

Analyst recommendations: Apple, Oracle, Progressive, Dollar Tree...	12:15pm
Mizuho Boosts Price Target on Vaxcyte to $163 From $113, Maintains Outperform Rating	10:38am	MT
Vaxcyte Insider Sold Shares Worth $1,263,912, According to a Recent SEC Filing	07-25	MT
Vaxcyte Insider Sold Shares Worth $649,325, According to a Recent SEC Filing	07-22	MT
Vaxcyte Insider Sold Shares Worth $425,000, According to a Recent SEC Filing	07-17	MT

Vaxcyte, Inc. Share Price

Equities

PCVX

US92243G1085

Biotechnology & Medical Research

Valuation: Vaxcyte, Inc.

Chart: Vaxcyte, Inc.

Latest news: Vaxcyte, Inc.

Last Transcript: Vaxcyte, Inc.

Analysts' recommendations: Vaxcyte, Inc.

Press Releases: Vaxcyte, Inc.

News in other languages: Vaxcyte, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Vaxcyte, Inc.

ETFs: Vaxcyte, Inc.

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly earnings, Rate of surprise

Vaxcyte Announces Closing of $1.5 Billion Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares	09-06	GL
Vaxcyte Announces Pricing of $1.3 Billion Public Offering	09-05	GL
Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants	09-03	GL
Vaxcyte : September Investor Presentation	09-03	PU
Vaxcyte : VAX-31 Phase 1/2 Study Results	09-03	PU

Bourse Zurich: les indices en ordre dispersé pour entamer la semaine	16/10/23
Aktien Schweiz von gestiegener Riskoneigung belastet	16/10/23
Lonza: contratto per produzione vaccini a Visp, fino a 300 impieghi	16/10/23
Lonza produira les vaccins expérimentaux de l'américain Vaxcyte	16/10/23
Lonza produziert Impfstoffkandidaten von Vaxcyte	16/10/23

1 day	+3.32%
1 week	+42.74%
Current month	+42.74%
1 month	+48.00%
3 months	+62.43%
6 months	+58.59%
Current year	+83.57%

Director	Title	Age	Since
Jeff Fairman FOU	Founder	60	26/05/13
Grant Pickering FOU	Founder	56	26/05/13
Andrew Guggenhime DFI	Director of Finance/CFO	55	30/04/20

Name	Weight	AuM	1st Jan change	Investor Rating
LEVERAGE SHARES 3X LONG BIOTECHNOLOGY ETP SECURITIES - USD	0.27%	0 M€	0.00%	-
LEVERAGE SHARES -3X SHORT BIOTECHNOLOGY ETP SECURITIES - USD	0.10%	0 M€	0.00%	-

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi. ($)
VAXCYTE, INC.	+3.32%	+42.74%	+127.47%	+343.56%	14.26B
REGENERON PHARMACEUTICALS, INC.	+1.17%	-3.37%	+37.81%	+77.18%	124B
VERTEX PHARMACEUTICALS INCORPORATED	+0.66%	-5.00%	+37.33%	+150.47%	122B
ARGENX SE	+0.14%	+6.96%	+1.61%	+79.07%	32.94B
BIONTECH SE	+11.77%	+13.95%	-16.32%	-71.39%	23.9B
BEIGENE, LTD.	+1.04%	+0.80%	+0.35%	-42.70%	20.54B
GENMAB A/S	+0.90%	+0.08%	-27.80%	-32.75%	17.42B
WUXI APPTEC CO., LTD.	+1.57%	+4.43%	-48.28%	-72.01%	15.77B
SAREPTA THERAPEUTICS, INC.	-0.95%	-5.96%	+6.49%	+58.60%	12.18B
INSMED INCORPORATED	+1.10%	-6.08%	+173.50%	+155.22%	12.34B
Average	+2.07%	+4.63%	+29.22%	+64.53%	39.45B
Weighted average by Cap.	+1.58%	+0.14%	+29.59%	+85.36%

Manager	Title	Age	Since
Grant Pickering FOU	Founder	56	26/05/13
K. Hirth BRD	Director/Board Member	72	31/08/16
Heath Lukatch BRD	Director/Board Member	56	30/04/18

	2024 *	2025 *
Net sales	-	-
Net income	-512M -39.12B	-597M -45.58B
Net Debt	-	-